The definitive agreement provides a clear path to closing. Key catalysts to watch: (1) SEC review of the F-4 registration statement, (2) shareholder votes for both SPAC and ArcheNova, and (3) Nasdaq listing approval. The $2.0 billion valuation for a biotech company will be scrutinized; any material adverse change or regulatory delay could impact the timeline.
Price Chart
Executive Summary
Horizon Space Acquisition I Corp. (HSPOF) has entered into a definitive business combination agreement to merge with ArcheNova Biotech Corp., a biotech company. The transaction implies a $2.0 billion equity value for ArcheNova. The deal is structured as a two-step merger through newly formed acquisition entities, with the SPAC's trust account proceeds used to fund the transaction and provide working capital. The combined entity will be named ArcheNova Technology Co., Ltd and will list on Nasdaq.
Key Financial Metrics
Key Facts
- Business combination agreement signed on October 12, 2026 between Horizon Space Acquisition I Corp. and ArcheNova Biotech Corp.
- Implied equity value of ArcheNova Biotech Corp. is $2.0 billion.
- Transaction structured as two mergers: Merger Sub I merges with SPAC, then Merger Sub II merges with ArcheNova Biotech Corp.
- SPAC had approximately $760,873 in its trust account as of October 5, 2026.
- SPAC units, ordinary shares, and warrants are quoted on OTC Markets under symbols HSPOF, HSPUF, and HSPWF.
- Combined company to be named ArcheNova Technology Co., Ltd and will seek listing on Nasdaq.
- Sponsor and directors have agreed to support the transaction and not redeem their shares.
- Key shareholders of ArcheNova have entered into a support agreement to vote in favor of the merger.
- Registration rights agreement and lock-up agreement are part of the transaction documents.
- The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the U.S. Internal Revenue Code.
Financial Impact
Implied equity value of $2.0 billion for ArcheNova Biotech Corp. SPAC trust account had approximately $760,873 as of October 5, 2026.
Risk Factors
- Transaction subject to shareholder approvals and regulatory clearances, including SEC review of the F-4.
- SPAC shareholders may elect to redeem their shares, reducing cash available for the combined company.
- ArcheNova Biotech Corp. is a biotech company; its valuation of $2.0 billion may be contingent on pipeline progress and FDA approvals.
- The combined company must meet Nasdaq listing requirements, which are subject to market conditions.
- Any material adverse change in ArcheNova's business or financial condition could terminate the agreement.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001929980-26-000542 |
| Document: hspo_ex103.htm | 0001929980-26-000542 |
| Document: hspo_ex101.htm | 0001929980-26-000542 |
| Document: hspo_ex105.htm | 0001929980-26-000542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 425 | $11.99 $11.99 | · 0.00% | ▲ +1.15% | $12.29 (+2.50%) |
Oct 13, 2026 14d ago | 8-K | $11.99 $11.99 | · 0.00% | ▲ +1.15% | $12.29 (+2.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers